| Name | Title | Contact Details |
|---|---|---|
Ashwin Altekar |
Vice President of Information Security | Profile |
At Bayshore, we believe in creating special moments for our clients each and every day, whether at the bedside, on the phone or in the clinic. These moments touch the lives of our clients and our employees, and they guide the way we run our business. These moments inspire, change and encourage us. They are what we call the Bayshore difference. Bayshore HealthCare is one of the country`s leading providers of home and community health care services and is a Canadian-owned company.
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex`s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product, Tru Niagen® — available at www.truniagen.com and through partnerships with global retailers and distributors.
The loge Group LLC is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At OmniSonics, we are a team of highly dedicated people focused on building technology that will allow physicians to improve the quality of life for patients suffering from vascular diseases - such as deep vein thrombosis (DVT) and peripheral arterial
Since 2007, Genalyte has been guided by the vision of taking a single drop of blood, performing panels of tests and returning accurate and reproducible results within a few minutes. We launched our first instrument in 2012 in the pharmaceutical industry and academia for a range of healthcare applications including autoimmune disease monitoring, screening of cancer biomarkers, testing for infectious agents and detecting anti-drug antibodies. By reducing tests to a microscopic size in a highly multiplex environment on the surface of silicon chips we are able to generate more information from a smaller sample in less time than conventional techniques.